Systems and Methods to Identify and Treat Subjects at Risk for Obstetrical Complications

2. The method of claim 1, wherein the treating of the angiogenic and anti-angiogenic imbalance treats an obstetrical complication.

3. The method of claim 2, wherein the obstetrical complication is fetal death (FD).

4. The method of claim 3, wherein the FD is associated with maternal floor infarction or placental lesions consistent with maternal vascular underperfusion.

5. The method of claim 1, wherein the water-soluble statin is pravastatin.

6. The method of claim 5, wherein the effective amount of pravastatin is 20 mg/day.

7. The method of claim 5, further comprising administering heparin and aspirin to the subject.

9. The method of claim 1, wherein the sample is blood or serum.

10. The method of claim 1, comprising determining a ratio of PIGF/sVEGFR-1 and a ratio of PIGF/sEng.

11. The method of claim 1, wherein the sample is obtained during a third trimester of a pregnancy.

12. The method of claim 1, wherein the sample is obtained between a 24th week of pregnancy and a 28th week of pregnancy.

13. The method of claim 1, wherein the sample is obtained between a 30th week and a 34th week of pregnancy.